



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>4</sup> :</b> <b>C07K 7/08, A61L 27/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 89/ 01493</b> <b>(43) International Publication Date:</b> 23 February 1989 (23.02.89)
<b>(21) International Application Number:</b> PCT/US88/02745 <b>(22) International Filing Date:</b> 12 August 1988 (12.08.88)  <b>(31) Priority Application Number:</b> 087,157 <b>(32) Priority Date:</b> 19 August 1987 (19.08.87) <b>(33) Priority Country:</b> US  <b>(71) Applicant:</b> REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street S.E., Minneapolis, MN 55455 (US).  <b>(72) Inventors:</b> CHARONIS, Aristidis, Spyridon ; 3536 Dupont Avenue South, Minneapolis, MN 55408 (US). FURCHT, Leo, Theodore ; 2100 West 21st Street, Minneapolis, MN 55405 (US).		<b>(74) Agent:</b> HAMRE, Curtis, B.; Merchant, Gould, Smith, Edell, Welter & Schmidt, 1600 Midwest Plaza Building, Minneapolis, MN 55402 (US).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> POLYPEPTIDES WITH LAMININ ACTIVITY  <b>(57) Abstract</b>  A composition which can bind heparin and promote cellular adhesion is provided which consists essentially of a polypeptide of the formula: arg-tyr-val-val-leu-pro-arg-pro-val-cys-phe-glu-lys-gly-met-asn-tyr-thr-val-arg, or glu-leu-thr-asn-arg-thr-his-lys-phe-leu-glu-lys-ala-lys-ala-leu-lys-iso or mixtures thereof. Medical devices such as prosthetic implants, percutaneous devices and cell culture substrates coated with the polypeptide composition are also provided.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

## POLYPEPTIDES WITH LAMININ ACTIVITY

This invention was made with Government support under contract number CA 29995 by the National Institutes of Health. The Government has certain rights in the invention.

Background of the Invention

The adhesion of mammalian cells to the extracellular matrix is of fundamental importance in regulating growth, adhesion, motility and the development of proper cellular phenotype. This has implications for normal development, wound healing, chronic inflammatory diseases and tumor metastasis. Evidence accumulated over the last several years suggests that the molecular basis for the adhesion of both normal and transformed cells is complex and probably involves several distinct cell surface molecules. Extracellular matrices consist of three types of macromolecules: collagens, proteoglycans and noncollagenous glycoproteins.

One noncollagenous adhesive glycoprotein of interest is laminin. Laminin is a high molecular weight (~850,000) extracellular matrix glycoprotein found almost exclusively in basement membranes. (Timpl et al., J. of Biol. Chem., 254: 9933-9937 (1979)) The basement membrane is an ubiquitous, specialized type of extracellular matrix separating organ parenchymal cells from interstitial collagenous stroma. Interaction of cells with this matrix is an important aspect of both normal and neoplastic cellular processes. Normal cells appear to require an extracellular matrix for survival, proliferation, and differentiation, while migratory cells, both normal and neoplastic, must traverse the

-2-

basement membrane in moving from one tissue to another.

Laminin consists of three different polypeptide chains: B1 with 215,000 MW, B2 with 205,000 MW and A with 400,000 MW (Timpl and Dziadek, Intern. Rev. Exp. Path., 29: 1-112 (1986)) When examined at the electron microscopic level with the technique of rotary shadowing, it appears as an asymmetric cross, with three short arms 37nm long, each having two globular domains, and one long arm 77nm long, exhibiting a large terminal globular domain (Engel et al., J. Mol. Biol., 150: 97-120 (1981)). The three chains are associated via disulfide and other bonds. Structural data shows that laminin is a very complex and multidomain protein with unique functions present in specific domains.

Laminin is a major component of basement membranes and is involved in many functions. Laminin has the ability to bind to other basement membrane macromolecules and therefore contributes to the structural characteristics of basement membranes. Laminin has been shown to bind to type IV collagen (Charonis et al., J. Cell. Biol., 100: 1848-1853 (1985); Laurie et al., J. Mol. Biol., 189: 205-216 (1986)) exhibiting at least two binding domains (Charonis et al., J. Cell. Biol., 103: 1689-1697 (1986) Terranova et al., Proc. Natl. Acad. Sci. USA, 80: 444-448 (1983). Laminin also binds to entactin/nidogen (Timpl and Dziadek, supra and to basement membrane-derived heparin sulfate proteoglycan (Laurie et al., J. Mol. Biol., 189: 205-216 (1986). Laminin also has the ability to self-associate and form oligomers and polymers. Yurchenco et al., J. Biol. Chem., 260: 7636-7644 (1985). Another important functional aspect of laminin is its ability to associate with cell surface molecular receptors and consequently modify cellular phenotype in

-3-

various ways. A receptor for laminin with a molecular weight of about 68,000 has been observed in various cell types (Lesot et al., EMBO. J., 2: 861-865 (1983; Malinoff and Wicha, J. Cell. Biol., 96: 1475-1479 (1983). However, at least one other and maybe more cell surface receptors for laminin may exist. [See Timpl and Dziadek, supra; Horwitz et al., J. Cell. Biol., 101: 2134-2166 (1985)]. These might include sulfatides, gangliosides [Roberts et al., Proc. Natl. Acad. Sci. USA, 82: 1306-1310 (1985)] or various proteins and proteoglycans. These cell surface molecules may be mediators for the various effects that laminin has on cells. It is known that laminin can directly promote cell adhesion and cell migration of various cell types ranging from normal and malignant mesenchymal cells such as fibroblast and endothelial cells; to various epithelial cells Timpl and Dziadek, supra. However, the exact domains of laminin involved in such processes are not well established yet. For example, it is known that a heparin binding site exists on the A-chain, in the globule of the long arm of laminin (Ott et al., Eur. J. Biochem., 123: 63-72 (1982). However, the exact amino acid sequence of the A-chain is not known and therefore the related oligopeptide can not be identified yet.

Recently, a laminin fragment having a binding domain for a cell receptor without having a binding domain for type IV collagen has been described. U.S. Pat. No. 4,565,789 to Liotta et al. The Liotta patent discloses laminin fragments obtained by digestion of laminin with pepsin or cathepsin G. More specifically, digestion of laminin with pepsin or cathepsin G produces P1 ( $M_r$  280,000) and C1 ( $M_r$  350,000) fragments, wherein the long arm of the molecule is removed and also the globular end regions of the short arms are altered.

-4-

C1 and P1 fragments having similar molecular weights and binding capacities can also be obtained by digestion of laminin with plasmin and chymotrypsin. Laminin is also known to stimulate neurite outgrowth, a function that has been primarily assigned to the lower part of the long arm of laminin (Edgar et al., EMBO J., 3: 1463-1468 (1986)).

The functions that have been described above make laminin an important component of many diverse and clinically important processes such as cell migration, wound healing, nerve regeneration, tumor cell metastasis through vascular walls [Liotta, Am. J. Path., 117: 339-348 (1984); McCarthy et al., Cancer Met. Rev., 4: 125-152 (1985)], diabetic microangiopathy, and vascular hypertrophy due to hypertension. Laminin could also be used in various devices and materials used in humans. In order to better understand the pathophysiology of these processes at the molecular level, it is important to try to assign each of the biological activities that laminin exhibits to a specific subdomain or oligopeptide of laminin. If this can be achieved, potentially important pharmaceuticals based on small peptides producing specific functions of the native, intact molecule, can be synthesized. In order to do this, the exact amino acid sequence of the three laminin chains needs to be determined. Up to now, only the B1 chain has been published. Sasaki, Proc. Natl. Acad. Sci. USA, 84: 935-939 (1987).

Therefore, a need exists to isolate and characterize the subset of peptides within the B1 chain which are responsible for the wide range of biological activities associated with laminin. Such lower molecular weight oligopeptides would be expected to be more readily obtainable and to exhibit a narrower profile of biological activity than laminin itself or the B1 chain

-5-

thereof, thus increasing their potential usefulness as therapeutic or diagnostic agents.

Brief Description of the Invention

5       The present invention provides polypeptides which represent fragments of the B1 chain of laminin. The polypeptides can be prepared by conventional solid phase peptide synthesis. The formulas of the two preferred polypeptides are:

10       arg-tyr-val-val-leu-pro-arg-pro-val-cys-phe-glu-  
lys-gly-met-asn-tyr-thr-val-arg (F9)

and

15       glu-leu-thr-asn-arg-thr-his-lys-phe-leu-glu-lys-  
ala-lys-ala-leu-lys-iso. (F13)

Polypeptide F9 formally represents isolated laminin residues 641-660, while polypeptide F13 formally represents isolated laminin residues 1171-1188. The single letter amino acid codes for these polypeptides are RYVVLP RPVCFEKG MNYTVR and ELTNRTHKFLEKAKALKI.

20       These synthetic polypeptides were assayed for bioactivity and found to be potent promoters of heparin binding to synthetic substrates and of cell adhesion including adhesion of (a) endothelial cells, (b) melanoma cells and (c) fibrosarcoma cells, (d) glioma cells and (e) pheochromocytoma cells. Therefore, it is  
25       believed that these polypeptides may be useful to (a) assist in nerve regeneration, (b) promote wound healing and implant acceptance, (c) promote cellular attachment to culture substrata and (d) inhibit the metastasis of malignant cells. Due to the difference in the spectra  
30       of biological activities exhibited by polypeptides F9  
35

-6-

and F13, mixtures of these peptides is within the scope of the invention.

Furthermore, since it is expected that further digestion/hydrolysis of polypeptides F9 and F13 in vitro or in vivo will yield fragments of substantially equivalent bioactivity, such lower molecular weight polypeptides are considered to be within the scope of the present invention.

10

#### Brief Description of the Drawings

Figure 1 is a diagrammatic depiction of laminin, indicating the relative location of the A, B1 and B2 chains including globular regions located on each chain.

15

Figure 2 depicts the primary amino acid sequence of the B1 chain of laminin.

Figure 3 depicts the organization of domains on the laminin B1 chain;

20

Figure 4 is a graph depicting the heparin binding activity of polypeptide fragments of the invention.

Figure 5 is a graph depicting heparin binding activity of polypeptide fragments of the invention on plastic plates.

25

Figure 6 is a graph depicting inhibition of heparin binding to native laminin by polypeptide fragments of the invention.

30

Figures 7 and 8 are graphs depicting competition interaction between heparin and other glucosaminoglycans with polypeptides 9 and 13 of the present invention, respectively.

35

Figures 9-13 are graphs depicting cell adhesion to polypeptide fragments of the invention for aortic endothelial cells, M4 melanoma, MM fibrosarcoma, and C6 glioma, and PC12 pheochromocytoma cell lines,



-7-

respectively.

#### DETAILED DESCRIPTION OF THE INVENTION

##### Structure of Laminin and the B1 Chain

5 Referring to Figure 1, when examined by electron microscope utilizing rotary shadowing techniques, the structure of laminin appears as an asymmetric cross. The three short arms each have two globular domains and are 37 nm in length. The long arm  
10 exhibits one large terminal globular domain and is 77 nm in length. Engel et al., supra. As seen in Fig. 1 the three chains are associated via disulfide bonds and other bonds. Of the three polypeptide chains only the B1 chain having a molecular weight of 215,000 has been  
15 published. Sasaki et al., supra. The complete sequence of the B1 chain is shown in Figure 2. In Figure 3, a schematic of the domain structure of the B1 chain is shown, according to Sasaki et al., supra.

Binding sites for heparin are of special  
20 interest since heparin-like macromolecules such as heparan sulfate proteoglycans are present in basement membranes and cell surfaces and therefore their association with laminin may affect basement membrane structure and diverse cellular functions. As indicated  
25 previously, it is known that a heparin binding site exists on the A-chain, in the globule of the long arm of laminin (Ott et al, supra); the exact amino acid sequence is not known and therefore no related oligopeptide have been identified. According to the present  
30 invention, we have investigated domains of the B1 chain of laminin and synthesized a number of peptide fragments with cell-attachment promoting activity. The polypeptides synthesized and their properties are set forth in Tables 1 and 2, respectively. Peptides F9 and  
35 F13 are preferred embodiments of the present invention.

8

TABLE 1

F9: RYVVLP RPVCFEKG MNYTVR	20-mar 22# 641-660
F10: WEIFQRYRCLENSRSVVK	18-mar 22# 710-727
F11: NDTIDPEACOKDTGRCK	19-mar 22# 960-978
F12: VEGVEGPRCKKTRGY	16-mar 22# 1133-1148
F13: ELNRTHEFEKAKALKI	18-mar 22# 1171-1188
F14: VDSVERETVNERDI	14-mar 22# 1199-1212
F15: LEPSPFEQQEEQARL	17-mar 22# 1340-1356
F16: AQETTESADAPRAEL	16-mar 22# 1685-1700
F17: LEPKEDNQHYEDKA	16-mar 22# 1722-1737
F18: VCDPGYTSR	10-mar 22# 924-933

I Isoleucine	V Valine	L Leucine	F Phenylalanine
C Cysteine	M Methionine	A Alanine	G Glycine
T Threonine	W Tryptophan	S Serine	Y Tyrosine
P Proline	H Histidine	Q Glutamine	N Asparagine
K Lysine	R Arginine	E Glutamic acid	D Aspartic acid

TABLE 2

PEPTIDE	DOMAIN OF ORIGIN	HYDROPATHY INDEX*	# OF ARGININES AND LYSINES
F9	IV	-3.9	4
F11	III	-20.7	3
F12	III	-14.3	3
F13	II	-12.9	5
F14	II	-8.4	3
F15	II	-31.1	3
F16	I	-24.8	4
F17	I	-33.9	4
F18	III	-1.3	1

\*Hydropathy index values determined in accord with methodology of J. Kyte and R.F. Doolittle, J. Mol. Biol., 157: 105-132 (1982)

-9-

Synthesis of Polypeptides The polypeptides of the invention were synthesized using the Merrifield solid phase method. This is the method most commonly used for peptide synthesis, and it is extensively described by J. M. Stewart and J. D. Young in Solid Phase Peptide Synthesis, Pierce Chemical Company, pub., Rockford, IL (2d ed., 1984), the disclosure of which is incorporated by reference herein.

The Merrifield system of peptide synthesis uses a 1% crosslinked polystyrene resin functionalized with benzyl chloride groups. The halogens, when reacted with the salt of a protected amino acid will form an ester, linking it covalently to the resin. The benzyloxy-carbonyl (BOC) group is used to protect the free amino group of the amino acid. This protecting group is removed with 25% trifluoroacetic acid (TFA) in dichloromethane (DCM). The newly exposed amino group is converted to the free base by 10% triethylamine (TEA) in DCM. The next BOC-protected amino acid is then coupled to the free amino of the previous amino acid by the use of dicyclohexylcarbodiimide (DCC). Side chain functional groups of the amino acids are protected during synthesis by TFA stable benzyl derivatives. All of these repetitive reactions can be automated, and the peptides of the present invention were synthesized at the University of Minnesota Microchemical facility by the use of a Beckman System 990 Peptide synthesizer.

Following synthesis of a blocked polypeptide on the resin, the polypeptide resin is treated with anhydrous hydrofluoric acid (HF) to cleave the benzyl ester linkage to the resin and thus to release the free polypeptide. The benzyl-derived side chain protecting groups are also removed by the HF treatment. The polypeptide is then extracted from the resin, using 1.0 M

-10-

acetic acid, followed by lyophilization of the extract. Lyophilized crude polypeptides are purified by preparative high performance liquid chromatography (HPLC) by reverse phase technique on a C-18 column. A typical elution gradient is 0% to 60% acetonitrile with 0.1% TFA in H<sub>2</sub>O. Absorbance of the eluant is monitored at 220 nm, and fractions are collected and lyophilized.

Characterization of the purified polypeptide is by amino acid analysis. The polypeptides are first hydrolyzed anaerobically for 24 hours at 110°C in 6 M HCl (constant boiling) or in 4 N methanesulfonic acid, when cysteine or tryptophane are present. The hydrolyzed amino acids are separated by ion exchange chromatography using a Beckman System 6300 amino acid analyzer, using citrate buffers supplied by Beckman. Quantitation is by absorbance at 440 and 570 nm, and comparison with standard curves. The polypeptides may be further characterized by sequence determination. This approach is especially useful for longer polypeptides, where amino acid composition data are inherently less informative. Sequence determination is carried out by sequential Edman degradation from the amino terminus, automated on a Model 470A gas-phase sequenator (Applied Biosystems, Inc.), by the methodology of R. M. Hewick et al., J. Biol. Chem., 256, 7990 (1981).

The invention will be further described by reference to the following detailed examples. In the examples the prefix "F" before each polypeptide referenced in Tables 1 and 2 has been dropped.

30

#### EXAMPLE 1. Heparin Binding Assay

The assay for heparin binding utilizes nitrocellulose sheets as substrata to bind peptides or proteins to be tested for heparin binding activity.

35 Peptides 9 and 11-18 were solubilized in 50 mM

-11-

NH<sub>3</sub>HCO<sub>3</sub> to form solutions of 1 mg/ml. Each solution was serially diluted 1:1 in the same buffer producing concentrations from 1 mg/ml to 1 µg/ml. Nitrocellulose sheets which had been presoaked in 50 mM NH<sub>3</sub>HCO<sub>3</sub> were placed in a 96 well dot blot apparatus (Bethesda Research Laboratories, Bethesda, MD, and 100 µl of various concentrations of each peptide were aspirated through the wells. Each well was then washed three times with binding buffer (10 mM Tris-HCl, pH 8.0, 0.15 M NaCl), and the filters were removed and allowed to air dry overnight. The filters were then equilibrated for 5 minutes at room temperature in binding buffer which contained 10 mM CaCl<sub>2</sub>. <sup>3</sup>H-heparin was then diluted to a concentration of 50,000 cpm/ml in binding buffer (with Ca<sup>++</sup>), and nitrocellulose sheets were incubated in the presence of this mixture for 2 hours. The filters were then washed four times with binding buffer, and air dried. The individual spots of samples were cut out of the nitrocellulose, immersed in scintillation fluid and bound heparin was quantitated with a Beckman LS-3801 liquid scintillation counter. The results show that peptides 9 and 13 strongly bound <sup>3</sup>H-heparin (Figure 4). While several other peptides bound to <sup>3</sup>H-heparin the strength of adherence was less than that observed for peptide fragments 9 and 13.

#### EXAMPLE 2. Peptide Binding to Plastic Plates

In order to test the ability of the synthesized peptides (9 and 11-18) to bind to 96-well plastic plates (in which experiments with cultured cell lines can be performed), we did an experiment similar to that described above in Example 1. Stock solutions of peptides 9 and 11-18, laminin and BSA at a maximum concentration of 1 mg/ml were prepared and serially diluted in PBS + NaN<sub>3</sub> producing final concentration from 1 mg/ml to 1 µg/ml. Fifty µl from each con-

-12-

centration was coated on the 96-well plates and left to dry overnight at 28 C. Then, wells were treated for two hours with 200  $\mu$ l of 2 mg/ml BSA in 6 mM phosphate, 100 mM NaCl, 68  $\mu$ M CaCl<sub>2</sub>, pH 6.8 (wash buffer) in order to minimize non-specific binding. Next 50  $\mu$ l of <sup>3</sup>H-heparin (10  $\mu$ g/ml) was added (50,000 cpm/well) for two hours at 37 C. The wells were then washed three times with wash buffer containing 0.05% Triton X-100 and finally they were incubated for thirty minutes at 60 C with 200  $\mu$ l of 0.5 N NaOH and 1% SDS. The amount of <sup>3</sup>H-heparin bound at each peptide concentration was quantitated as described above in Example 1. The results shown in Figure 5 indicate that peptide 9 and laminin bind heparin very well and that peptide 13 also binds heparin but less extensively.

EXAMPLE 3. Inhibition of Heparin Binding  
to Laminin by Peptide Fragments

Peptides 9, 11-14 and 16 in solution (and not absorbed to plastic), were screened for the ability to inhibit the binding of heparin to intact, native laminin coated on plastic. This experimental approach avoids problems due to differential coating of peptides in heparin binding assays. Laminin at 60  $\mu$ g/ml in PBS was coated on 96-well plates, using 50  $\mu$ l per well and dried overnight at 28 C. The wells were then treated for two hours with 2 mg/ml BSA in wash buffer (described above in Example 2). Peptides at various dilutions ranging from 1 mg/ml to 1  $\mu$ g/ml in PBS and CHAPS (Cholamido-propyl-dimethyl-Ammonio-Propane-Sulfonate) (a detergent used to avoid non-specific sticking) were co-incubated with a standard amount of <sup>3</sup>H-heparin (25,000 cpm per well 5  $\mu$ g/ml final concentration) for two hours at 37 C and the mixture was then transferred to the laminin coated plate (50  $\mu$ l)

-13-

and allowed to incubate for another two hours at 37 C. The wells were then washed and radioactivity was counted as described above. Results shown in Figure 6 indicate that peptides 9 and 13 interact most strongly with heparin by this assay.

EXAMPLE 4: Heparin/Peptide Interaction Specificity

To check whether charge was the main factor in the interaction between heparin and peptides 9 and 13, or whether the heparin structure was also critical to this interaction heparin along with two other sulfated glucosaminoglycans, dextran sulfate and chondroitin sulfate were used in competition experiments. A standard amount of 3.1 µg per well of peptide 9 and 12.5 µg per well of peptide 13 were coated on 96-well plates as described above. We used different concentrations for each peptide in order to monitor the interaction with heparin at a good level of sensitivity, as suggested from the results of Example 2. Wells were treated for two hours with 2 mg/ml BSA in wash buffer. Then, a final volume of 50 µl was added to each well, containing a standard amount of <sup>3</sup>H-heparin (50,000 cpm per well) and various amounts of non-radioactive heparin, dextran sulfate and dermatan sulfate. After incubating for two hours at 37 C, the wells were washed and radioactivity was counted as described above in Example 1. As shown in Figure 7 (for peptide 9) and Figure 8 (for peptide 13) a 50% inhibition of the binding of <sup>3</sup>H-heparin can be achieved by  $3 \times 10^{-12}$  M of heparin. Ten to one hundred times more molar concentration of dextran sulfate and dermatan sulfate are needed to produce the same effect. Therefore, the structure of heparin is a crucial factor for this interaction.

EXAMPLES 1-4 indicated that peptides 9 and 13 are domains on the B1 chain of laminin that can bind

-14-

specifically with heparin-like molecules.

EXAMPLE 5: Adhesion of Endothelial Cells

A. Isolation of Bovine Aortic Endothelial Cells

5           Bovine aortic endothelial cells were isolated according to the following protocol. Aortas were obtained from a local slaughterhouse, washed in cold phosphate buffered saline (PBS) (136 mM NaCl, 2.6 mM KCl, 15.2 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.2) and processed within 2  
10 hours. Crude collagenase (CLS III, 125-145 units per mg dry weight, Cooper Biomedical) was used at 2 mg/ml in Dulbecco's modified Eagle's medium (DMEM) (GIBCO). The vessel was clamped at the distal end, filled with the collagenase-PBS solution and digestion was carried  
15 out for 10 minutes. The luminal contents were harvested, followed by the addition of fresh collagenase for two additional 10-minute periods. The enzyme-cell suspensions were added to an equal volume of DMEM containing 10% fetal bovine serum (FBS) to inhibit the  
20 enzyme and spun in a centrifuge at 400 x g for 10 minutes. The resulting cell pellet was resuspended in DMEM containing 10% FBS, 100 units/ml of penicillin G, 100 µg/ml of streptomycin and 100 µg/ml of crude fibroblast growth factor. Cells are cultured in 75 cm<sup>2</sup> flasks in  
25 a humidified 5% CO<sub>2</sub> atmosphere at 37°C. Cultures were fed twice a week with the same medium and cells were used in assays when approximately 75% confluent. Cells were identified as endothelial in nature by characteristic cobblestone morphology, contact inhibition of  
30 growth upon reaching confluency, and positive immunofluorescent staining for factor VIII:RAg (Miles Laboratories) [S. Schwartz, In Vitro, 14, 966 (1978)]. Only endothelial cells, megakaryocytes and platelets are known to contain the factor VIII:RAg. This method  
35 routinely gives a high yield of endothelial cells with



-15-

little contamination (less than 5%) by smooth muscle cells, pericytes or fibroblasts as judged by phase contrast microscopy as well as by immunostaining.

5     B.     Aortic Endothelial Cell Adhesion Assay

Adhesion was measured using 96 well microtiter plates adsorbed with three different amounts (0.1; 1.0; and 10.0 µg/per well) of peptides 9, 11-18, BSA and laminin. Cultures of cells which were 60-80% confluent  
10     were metabolically labeled for 24 hours with the addition of 3 mCi/ml of <sup>3</sup>H-amino acid mixture. On the day of the assay, the cells were harvested by trypsinization, the trypsin was inhibited by the addition of serum, and the cells were washed free of this mixture and resuspended in DMEM buffered with HEPES at pH  
15     7.2. The adhesion medium also contained 2 mg/ml BSA. The cells were adjusted to a concentration of 3-4 x 10<sup>4</sup>/ml, and 100 µl of this cell suspension was added to the wells. The assay mixture was then incubated at  
20     37°C for 120 minutes. At the end of the incubation, the wells were washed with warm PBS containing 10 mM Ca<sup>++</sup>, and the adherent population was solubilized with 0.5 N NaOH containing 1% sodium dodecyl sulfate. The solubilized cells were then quantitated using a liquid  
25     scintillation counter. Each determination was done in triplicate. The results of this study are summarized in Fig. 9 below.

These results indicate that peptides 9 and 13 and 12 and 18 are potent promoters of endothelial cell  
30     adhesion. Thus, these peptides may be useful as a synthetic substratum to promote endothelial cell adhesion.

-16-

Example 6. Adhesion of Cancer CellsA. Isolation of and Cell Adhesion for M4 cell line

Highly metastatic murine melanoma cells, K-1735-M4 were originally provided by Dr. I.J. Fidler of Anderson Hospital, University of Texas Health Sciences Center, Houston, Texas. When the cells were received, a large number of early passage cells were propagated and frozen in liquid nitrogen. The tumor cells are usually cultured in vitro for no longer than six weeks. Following this period, the cells are discarded and new cells withdrawn from storage for use in further in vitro or in vivo experiments. This precaution is taken to minimize phenotypic drift that can occur as a result of continuous in vitro passage. The cells were cultured in Dulbecco's Modified Eagle's Medium containing 5% heat inactivated fetal calf serum. The cultures were grown in 37°C incubators with a humidified atmosphere containing 5% CO<sub>2</sub>. Cells were subcultured twice weekly by releasing cells gently from the flask, using 0.05% trypsin and 1 mM EDTA.

The melanoma cells were pulsed in the same fashion as the endothelial cells described hereinabove, except that 3 mCi/ml <sup>3</sup>HTd(tritiated thymidine) was added to each culture instead of amino acids. The labeled cells were harvested as described for the endothelial cells. The cell adhesion assay was identical to that described hereinabove for the bovine aortic endothelial cell assay. The results of this assay are summarized in Fig. 10, below.

30

B. Isolation of and Cell Adhesion Assay for MM fibrosarcoma Cell Line

Murine fibrosarcoma cells (uv-2237-MM) were originally provided by Dr. I.J. Fidler of Anderson Hospital, University of Texas Health Sciences Center,

35

-17-

Houston, TX. Culturing, labeling and harvesting techniques were as described in part A. Cell adhesion assay was performed as described in Example 5. The results of this assay are summarized in Fig. 11 below.

5

C. Isolation of and Cell Adhesion Assay for C6 Cell Line

10 Rat C6 glioma cell line was purchased from the American Type Culture Collection (identification number CCL 107). Culturing techniques were as described in part A. Labelling and harvesting techniques were as described in Example 5. Cell adhesion assay was performed as described in Example 5. The results of this assay are summarized in Figure 12 below.

15

D. Isolation of and Cell Adhesion Assay for PC12 Pheochromocytoma Cell Line

20 PC12 rat pheochromocytoma cells were provided by Dr. P. Letourneau of the Department of Anatomy, University of Minnesota, Minneapolis, MN. Culturing techniques were as described in part A. Labelling and harvesting techniques were as described in Example 5. Cell adhesion assay was performed as described in Example 5. The results of this assay are summarized in  
25 Figure 13 below.

EXAMPLES 5 and 6A-D indicate that peptides 9 and 13 are potent promoters of cell adhesion for a wide range of cell lines.

30 A number of practical applications for the polypeptides of the present invention can be envisioned. Such applications include the promotion of the healing of wounds caused by the placement of synthetic substrata within the body. Such synthetic substrata can include artificial vessels, intraocular contact  
35 lenses, hip replacement implants and the like, where

-18-

cell adhesion is an important factor in the acceptance of the synthetic implant by normal host tissue.

As described in U.S. patent No. 4,578,079, medical devices can be designed making use of these polypeptides to attract cells to the surface in vivo or even to promote the growing of a desired cell type on a particular surface prior to grafting. An example of such an approach is the induction of endothelial cell growth on a prosthetic device such as a blood vessel, heart valve or vascular graft, which is generally woven or knitted from nitrocellulose or polyester fiber, particularly Dacron™ (polyethylene terephthalate) fiber. Most types of cells are attracted to laminin and to the present polypeptides. Endothelial cells and fibroblastic cells are especially attracted to the present polypeptides. The latter point indicates the potential usefulness of these defined polypeptides in coating a patch graft or the like for aiding wound closure and healing following an accident or surgery. The coating and implantation of synthetic polymers may also assist in the regeneration of nerves following crush traumae, e.g., spinal cord injuries.

In such cases, it may be advantageous to couple the peptide to a biological molecule, such as collagen, a glycosaminoglycan or a proteoglycan. It is also indicative of their value in coating surfaces of a prosthetic device which is intended to serve as a temporary or semipermanent entry into the body, e.g., into a blood vessel or into the peritoneal cavity, sometimes referred to as a percutaneous device. Such devices include controlled drug delivery reservoirs or infusion pumps.

Also, the polypeptides of the present invention can be used to promote cell adhesion of various cell types to naturally occurring or artificial

-19-

substrata intended for use in vitro. For example, a culture substrate such as the wells of a microtiter plate or the medium contacting surface of microporous fibers or beads, can be coated with the cell-attachment polypeptides. This can obviate the use of laminin in the medium, thus providing better defined conditions for the culture as well as better reproducibility.

As one example of commercial use of cell-attachment surfaces, Cytodex particles, manufactured by Pharmacia, are coated with gelatin, making it possible to grow the same number of adherent cells in a much smaller volume of medium than would be possible in dishes. The activity of these beads is generally dependent upon the use of coating protein in the growth medium and the present polypeptides are expected to provide an improved, chemically-defined coating for such purposes. Other surfaces or materials may be coated to enhance attachment, such as glass, agarose, synthetic resins or long-chain polysaccharides.

In the past, selected laminin domains have been studied for ability to decrease the metastatic potential of invasive cell lines (McCarthy et al, supra). This effect is mediated via the saturation and therefore neutralization of cell surface receptors for laminin. In accordance with the present invention, the data presented herein suggest that receptors for the polypeptides 9 and 13 should exist on cell surfaces of malignant cells. Consequently, these polypeptides could be used to block laminin receptors of metastatic cells and therefore reduce their metastatic potential.

The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.

-20-

WHAT IS CLAIMED IS:

1. A composition consisting essentially of a polypeptide of the formula:

5 arg-tyr-val-val-leu-pro-arg-pro-val-cys-phe-glu-lys-gly-met-asn-tyr-thr-val-arg, or

glu-leu-thr-asn-arg-thr-his-lys-phe-leu-glu-lys-ala-lys-ala-leu-lys-iso or mixtures thereof.

10

2. A prosthetic device designed for placement in vivo, comprising a surface coated with a composition consisting essentially of a polypeptide of the formula:

-

15

arg-tyr-val-val-leu-pro-arg-pro-val-cys-phe-glu-lys-gly-met-asp-tyr-thr-val-arg, or

glu-leu-thr-asp-arg-thr-his-lys-phe-leu-glu-lys-ala-lys-ala-leu-lys-iso or mixtures thereof.

20

3. The prosthetic device of claim 2, wherein said surface constitutes a portion of a vascular graft.

- 25 4. A prosthetic device of claim 2 wherein said surface is made of a synthetic resin fiber.

5. The prosthetic device of claim 2, wherein said surface constitutes a portion of an intraocular contact lens.

30

6. The prosthetic device of claim 2, wherein said surface constitutes a portion of a hip replacement implant.

35

-21-

7. The prosthetic device of claim 2, wherein said surface constitutes a portion of a percutaneous device.
- 5 8. A prosthetic device in accordance with claim 4 wherein said synthetic resin fiber is selected from the group consisting of nitrocellulose or polyester.
- 10 9. A prosthetic device in accordance with claim 4 wherein said synthetic resin fiber is a polyethylene terephthalate.
- 15 10. A cell culture substrate having a surface coated with a composition consisting essentially of a polypeptide of the formula:
- arg-tyr-val-val-leu-pro-arg-pro-val-cys-phe-glu  
lys-gly-met-asn-tyr-thr-val-arg, or
- 20 glu-leu-thr-asn-arg-thr-his-lys-phe-leu-glu-lys-  
ala-lys-ala-leu-lys-iso or mixtures thereof.
- 25 11. The cell culture substrate of claim 10 wherein said surface is made of a synthetic resin.
12. The cell culture substrate of claim 10 wherein said surface constitutes a portion of a bead.
- 30 13. The cell culture medium of claim 10 wherein said surface constitutes a portion of a microporous fiber.
- 35 14. The cell culture medium of claim 10 wherein said surface constitutes the wells of a microtiter

-22-

plate.

15. A polypeptide corresponding to a B1 chain fragment  
of laminin having specific binding capacity for  
5 heparin.

16. The polypeptide fragment of claim 15 wherein said  
polypeptide fragment is:

10 arg-tyr-val-val-leu-pro-arg-pro-val-cys-phe-glu-  
lys-gly-met-asn-tyr-thr-val-arg.

- 17. The polypeptide fragment of claim 15 wherein said  
polypeptide fragment is:

15 glu-leu-thr-asn-arg-thr-his-lys-phe-leu-glu-lys-  
ala-lys-ala-leu-lys-iso.

18. The polypeptide fragment of claim 15 wherein said  
20 fragment directly promotes cell adhesion.



1 / 1 3

FIG. 1





FIG. 3

## LAMININ BETA 1-CHAIN

## FIG. 2


10	20	30	40	50	60	70
QEPEFSYGCA	EGSCYPATGD	LLIGRAQKLS	VTSTCGLEKP	EPYCIVSHLQ	EDKKCFICDS	RDPYHETLNP
80	90	100	110	120	130	140
DSHLIENVVT	TFAPNRLKIW	VQSENGVENV	TIQLALEAEF	HFTHLIMTFK	TFRPAAMLIE	RSSDFGKTWG
150	160	170	180	190	200	210
VYRYFAYDCE	SSFPGISTGP	MKKVDDIICD	SRYSDIEPST	EGEVIFRALD	PAFKIEDPYS	PRIQNLLKIT
220	230	240	250	260	270	280
NLRIFVKLH	TLGDNLLDSR	MEIREKYYIA	VYDMVVRGNC	FCYGHASECA	PVDGVNEEVE	GMVHGHCPCR
290	300	310	320	330	340	350
HNTKGLNCEL	CMDFYHDLPW	RPAEGRNSNA	CKKCNCNEHS	SSCHFDMAVF	LATGNVSGGV	CDNCQHNTMG
360	370	380	390	400	410	420
RNCEQCKPFY	FQHPERDIRD	PNLCEPCTCD	PAGSENGGIC	DGYTDFSVGL	IAGQCRCKLH	VEGERCDVCK
430	440	450	460	470	480	490
EGFYDLSAED	PYGCKSCACN	PLGTTGGNP	CDSETGYCYC	KRLVTGQRCD	QCLPQHWGLS	NDLDGCRPCD
500	510	520	530	540	550	560
CDLGGALNNS	CSEDSGQCSC	LPHMIGRQCN	EVESGYYFTT	LDHYIYEAEE	ANLGPVGVVV	ERQYIQDRIP
570	580	590	600	610	620	630
SWTGPGFVRV	PEGAYLEFFI	DNIPYSMEYE	ILIRYEPQLP	DHWEKAVITV	QRPGKIPASS	RCGNTVPDDD
640	650	660	670	680	690	700
NQVVSLSPGS	RYVVLPRPVC	FEKGMNYTVR	LLEPQYTASG	SDVESPYTFI	DSLVLMPYCK	SLDIFTVGGG
710	720	730	740	750	760	770
GDGEVTNSAW	ETFQRYRCLE	NSRSVVKTPM	TDVCRNIIFS	ISALIHQTGL	ACECDPQGS	SSVCDPNGGQ
780	790	800	810	820	830	840
CQCRPNVVGR	TCNRCAPGTF	GFGPNGCKPC	DCHLQGSASA	FCDAITGQCH	CFQGIYARQC	DRCLPGYWGF
850	860	870	880	890	900	910
PSCQPCQCNG	EALDCDVTG	ECLSCQDYTT	GHNCERCLAG	YYGDPIIGSG	DHCRPCPCPD	GPDSGRQFAR
920	930	940	950	960	970	980
SCYQDPVTLQ	LACVCDPGYI	GSRCDDCASG	FFGNPSQFGG	SCQPCQCHHN	IDTTDPEACD	KDTGRCLKCL
990	1000	1010	1020	1030	1040	1050
YHTEGDHCQL	CQYGYGDAL	RQDCRKVCN	YLGTVKEHCN	GSDCECDKAT	GQCSCLPNVI	GQNCDRCAPN
1060	1070	1080	1090	1100	1110	1120
TFQLASGTGC	GPCNCNAAHS	FGPSCNEFTG	QCQCMPPGGG	RTCSECQELF	VGDPDVECRA	CDCDPRGIET
1130	1140	1150	1160	1170	1180	1190
PQCDQSTGQC	VCVEGVGPR	CDKCTRGYSG	VFPDCTPCEQ	CFALWDAIIG	ELTNRTHKFL	EKAKALKRISG
1200	1210	1220	1230	1240	1250	1260
VIGPYRETVD	SVEKKVNEIF	DILAQSPAEE	PLKNIGILFE	EAEFLTRDVT	ERMAQVEVCL	TDTASQSNCT

## FIG. 2 CONTINUED

1270	1280	1290	1300	1310	1320	1330
AGELGALQAG	AESLDKTVKE	LAEQLEFIKN	SDIQGALDSI	TKYFQMSLEA	EKRVNASTTD	PNSTVEQSAL
1340	1350	1360	1370	1380	1390	1400
TRDRVEDLML	ERESPFREQQ	EEQABLLDEL	AGXLQSLDLS	AAAQMTGCTP	PGADCSESEC	GGPNCRTDEG
1410	1420	1430	1440	1450	1460	1470
EKKCGGPGCG	GLVTVAHSAV	QKAMDFDRDV	LSALAEVEQL	SKMVSEAKVR	ADEAKQNAQD	VLLKTNATKE
1480	1490	1500	1510	1520	1530	1540
KVDESNEDLR	NLIKQIRNFL	TEDSADLDSI	EAVANEVLKS	GNASTPQQLQ	NLTEDIRERV	ETLSQVEVIL
1550	1560	1570	1580	1590	1600	1610
QQSAADIARA	ELLLEFAKRA	SKSATDVKVT	ADMVKEALEE	AEKAQVAAEK	AIKQADEDIQ	GTQNLLTSIE
1620	1630	1640	1650	1660	1670	1680
SETAASEETL	TNASQRISKL	ERNVEELKRK	AAQNSGEAEY	IEKVVSVKQ	NADDVKKTLD	GELDEKYKKV
1690	1700	1710	1720	1730	1740	1750
ESLIAQKTEE	SADARRKAEL	LQNEAKTLLA	QANSKLQLE	DLERKYEDNQ	KYLEDKAQEL	VRLEGEVRSL
1760						
LKDISEKVAV	YSTCL					


4 / 13

FIG. 4




5 / 13

FIG. 5




6 / 13

FIG. 6




7 / 13

FIG. 7



8 / 13


FIG. 8






9 / 13

FIG. 9




10 / 13

FIG. 10




1 1 / 1 3

FIG. II




12 / 13

FIG. 12



13 / 13

FIG. 13



# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 88/02745

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>4</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> :      C 07 K 7/08; A 61 L 27/00														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">IPC<sup>4</sup></td> <td style="padding: 5px; text-align: center;">C 07 K 7/00; A 61 L 27/00</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	IPC <sup>4</sup>	C 07 K 7/00; A 61 L 27/00								
Classification System	Classification Symbols													
IPC <sup>4</sup>	C 07 K 7/00; A 61 L 27/00													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category <sup>*</sup></th> <th style="border-bottom: 1px solid black;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 10%; border-bottom: 1px solid black;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">EP, A, 0021152 (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN e.V.) 7 January 1981 see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">P,Y</td> <td style="padding: 5px;">Chemical Abstracts, volume 109, 1988, (Columbus, Ohio, US), Y. Christiane et al.: "Laminin and type III procollagen peptide in human preovulatory follicular fluid", see page 398, abstract 108013q, &amp; Fertil. Steril. 1988, 50(1), 48-51 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">P,Y</td> <td style="padding: 5px;">Chemical Abstracts, volume 109, 1988, (Columbus, Ohio, US), R. Okazaki et al.: "Serum levels of laminin and type III procollagen peptide in relation to diabetic microangiopathy", see page 488, abstract 52615t, &amp; Tonyobyto (Tokyo) 1988, 31(1), 7-13 -- ./.</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> </tbody> </table>			Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	Y	EP, A, 0021152 (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN e.V.) 7 January 1981 see the whole document --	1	P,Y	Chemical Abstracts, volume 109, 1988, (Columbus, Ohio, US), Y. Christiane et al.: "Laminin and type III procollagen peptide in human preovulatory follicular fluid", see page 398, abstract 108013q, & Fertil. Steril. 1988, 50(1), 48-51 --	1	P,Y	Chemical Abstracts, volume 109, 1988, (Columbus, Ohio, US), R. Okazaki et al.: "Serum levels of laminin and type III procollagen peptide in relation to diabetic microangiopathy", see page 488, abstract 52615t, & Tonyobyto (Tokyo) 1988, 31(1), 7-13 -- ./.	1
Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
Y	EP, A, 0021152 (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN e.V.) 7 January 1981 see the whole document --	1												
P,Y	Chemical Abstracts, volume 109, 1988, (Columbus, Ohio, US), Y. Christiane et al.: "Laminin and type III procollagen peptide in human preovulatory follicular fluid", see page 398, abstract 108013q, & Fertil. Steril. 1988, 50(1), 48-51 --	1												
P,Y	Chemical Abstracts, volume 109, 1988, (Columbus, Ohio, US), R. Okazaki et al.: "Serum levels of laminin and type III procollagen peptide in relation to diabetic microangiopathy", see page 488, abstract 52615t, & Tonyobyto (Tokyo) 1988, 31(1), 7-13 -- ./.	1												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>*</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search            10th November 1988         </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report  <div style="text-align: right; font-weight: bold; font-size: 1.2em;">06 DEC 1988</div> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">           International Searching Authority  <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div> </td> <td style="border-bottom: 1px solid black; padding: 5px;">           Signature of Authorized Officer  <div style="text-align: right;">   <b>P.C.G. VAN DER PUTTEN</b> </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 10th November 1988	Date of Mailing of this International Search Report <div style="text-align: right; font-weight: bold; font-size: 1.2em;">06 DEC 1988</div>	International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: right;">   <b>P.C.G. VAN DER PUTTEN</b> </div>								
Date of the Actual Completion of the International Search 10th November 1988	Date of Mailing of this International Search Report <div style="text-align: right; font-weight: bold; font-size: 1.2em;">06 DEC 1988</div>													
International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: right;">   <b>P.C.G. VAN DER PUTTEN</b> </div>													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
P,Y	Chemical Abstracts, volume 109, 1988, (Columbus, Ohio, US), L. Hartl et al.: "The N terminus of laminin A chain is homologous to the B chains", see page 258, abstract 19085x, & Eur. J. Biochem. 1988, 173(3), 629-35	1
	--	
P,Y	Chemical Abstracts, volume 109, 1988, (Columbus, Ohio, US), Y. Iwamoto et al.: "Synthetic pentapeptide from the B1 chain of laminin promotes B16F10 melanoma cell migration", see page 444, abstract 4628c, & J. Cell. Physiol. 1988, 134(2), 287-91	1
	--	
Y	Chemical Abstracts, volume 108, 1988, (Columbus, Ohio, US), Y. Iwamoto et al.: "YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation", see page 29, abstract 68408t, & Science (Washington, D. C., 1983-) 1987, 238(4830), 1132-4	1
	--	
P,A	Chemical Abstracts, volume 107, 1987, (Columbus, Ohio, US), M. Sasaki et al.: "Structure of adhering protein, laminin, and determination of adhering peptide", see page 292, abstract 193110v, & Jikken Igaku 1987, 5(7), 650-2	1
	--	
A	Chemical Abstracts, volume 105, 1986, (Columbus, Ohio, US), P. Liesi et al.: "A synthetic peptide of laminin specifically inhibits neurite outgrowth of central neurons on laminin", see page 454, abstract 22265d, & Synth. Pept. Biol. Med., Proc. Labsystems Res. Symp. 1985, 209-11	1
	--	
Y	Chemical Abstracts, volume 99, 1983, (Columbus, Ohio, US), C.C. Howe et al.: "Structural analysis of three subunits of laminin from teratocarcinoma-derived parietal endoderm cells", see page 249, ./. .	1

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
P,A	abstract 66173j, & Dev. Biol. 1983, 98(2), 385-91 -- EP, A, 0244688 (BIO-POLYMERS) 11 November 1987 see the whole document	1,18



ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

US 8802745

SA 24231

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on 28/11/88  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0021152	07-01-81	DE-A- 2923583	18-12-80
		JP-A- 56001353	09-01-81
		US-A- 4340581	20-07-82
		AT-B- E6312	15-03-84
<hr/>			
EP-A- 0244688	11-11-87	AU-A- 7188687	29-10-87
		JP-A- 63023670	30-01-88
<hr/>			

EPO FORM 10479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

100  
100  
100